DE69108363T2 - Peptidylderivate. - Google Patents

Peptidylderivate.

Info

Publication number
DE69108363T2
DE69108363T2 DE69108363T DE69108363T DE69108363T2 DE 69108363 T2 DE69108363 T2 DE 69108363T2 DE 69108363 T DE69108363 T DE 69108363T DE 69108363 T DE69108363 T DE 69108363T DE 69108363 T2 DE69108363 T2 DE 69108363T2
Authority
DE
Germany
Prior art keywords
group
alkyl
amino
alkenyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69108363T
Other languages
English (en)
Other versions
DE69108363D1 (de
Inventor
John Robert Porter
Thomas Andrew Millican
John Richard Morphy
Nigel Robert Arnold Beeley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909026251A external-priority patent/GB9026251D0/en
Priority claimed from GB919110339A external-priority patent/GB9110339D0/en
Priority claimed from GB919110338A external-priority patent/GB9110338D0/en
Priority claimed from GB919112888A external-priority patent/GB9112888D0/en
Priority claimed from GB919112901A external-priority patent/GB9112901D0/en
Priority claimed from GB919115038A external-priority patent/GB9115038D0/en
Priority claimed from GB919115039A external-priority patent/GB9115039D0/en
Priority claimed from GB919115916A external-priority patent/GB9115916D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of DE69108363D1 publication Critical patent/DE69108363D1/de
Publication of DE69108363T2 publication Critical patent/DE69108363T2/de
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
DE69108363T 1990-12-03 1991-12-03 Peptidylderivate. Expired - Fee Related DE69108363T2 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB909026251A GB9026251D0 (en) 1990-12-03 1990-12-03 Netalloproteinase inhibitors
GB919110339A GB9110339D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919110338A GB9110338D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919112901A GB9112901D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919112888A GB9112888D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919115038A GB9115038D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115039A GB9115039D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115916A GB9115916D0 (en) 1991-07-23 1991-07-23 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
DE69108363D1 DE69108363D1 (de) 1995-04-27
DE69108363T2 true DE69108363T2 (de) 1995-08-31

Family

ID=27571285

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69108363T Expired - Fee Related DE69108363T2 (de) 1990-12-03 1991-12-03 Peptidylderivate.
DE69108529T Expired - Fee Related DE69108529T2 (de) 1990-12-03 1991-12-03 Peptidylderivate.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69108529T Expired - Fee Related DE69108529T2 (de) 1990-12-03 1991-12-03 Peptidylderivate.

Country Status (16)

Country Link
US (1) US5300501A (de)
EP (2) EP0489579B1 (de)
JP (2) JPH05503719A (de)
KR (2) KR927003520A (de)
AT (2) ATE120451T1 (de)
AU (2) AU652596B2 (de)
CA (2) CA2073510A1 (de)
DE (2) DE69108363T2 (de)
DK (1) DK0489579T3 (de)
ES (1) ES2069833T3 (de)
FI (2) FI923495A (de)
GB (2) GB2255340B (de)
GR (1) GR3015567T3 (de)
HU (3) HUT62263A (de)
NO (2) NO922967L (de)
WO (2) WO1992009564A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
JPH08503475A (ja) * 1992-11-25 1996-04-16 メルク エンド カンパニー インコーポレーテッド 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5652262A (en) * 1993-03-16 1997-07-29 British Biotech Pharmaceutical, Ltd. Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0692931A4 (de) * 1993-04-07 1996-03-20 Glycomed Inc Synthetische matrix-metalloprotease-inhibitoren und ihre verwendung
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
AU6575394A (en) * 1993-04-27 1994-11-21 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
WO1995004033A1 (en) * 1993-08-02 1995-02-09 Celltech Limited Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
DE69515702T2 (de) * 1994-01-20 2000-08-10 British Biotech Pharm L-Tertiär-leucin-2-pyridylamid
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995032944A1 (en) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
ES2133785T3 (es) * 1994-06-22 1999-09-16 British Biotech Pharm Inhibidores de metaloproteinasas.
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5857961A (en) * 1995-06-07 1999-01-12 Clarus Medical Systems, Inc. Surgical instrument for use with a viewing system
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
US6127427A (en) * 1995-11-23 2000-10-03 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
AU725831C (en) * 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
ES2181021T3 (es) 1996-09-10 2003-02-16 British Biotech Pharm Derivados citostaticos del acido hidroxamico.
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JPH10130217A (ja) * 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0887077A1 (de) * 1997-06-27 1998-12-30 Roche Diagnostics GmbH Verwendung von Azulenderivaten als Metalloproteaseinhibitoren
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
CA2373439A1 (en) * 1999-05-17 2000-11-23 Tetsunori Fujisawa Novel hydroxamic acid derivatives
JP2001031637A (ja) * 1999-05-17 2001-02-06 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PT1406893E (pt) 2001-06-15 2007-07-12 Vicuron Pharm Inc Compostos bicíclicos de pirrolidina
US7605132B2 (en) * 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
WO2005090387A2 (en) * 2004-03-23 2005-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone h2a peptide derivatives and analogs and methods of use thereof
US7528227B2 (en) * 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
KR20050086949A (ko) * 2002-12-27 2005-08-30 안지오테크 인터내셔날 아게 콜라졸리를 사용한 조성물 및 방법
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
DE102014206916A1 (de) 2014-04-10 2015-10-15 Wacker Chemie Ag Verfahren zur Ruthenium-katalysierten Umvinylierung von Carbonsäuren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5196412A (en) * 1991-03-06 1993-03-23 Johnson Matthey, Inc. Gallium compounds

Also Published As

Publication number Publication date
US5300501A (en) 1994-04-05
ATE120182T1 (de) 1995-04-15
CA2073513A1 (en) 1992-06-04
ATE120451T1 (de) 1995-04-15
KR927003520A (ko) 1992-12-18
EP0489579A1 (de) 1992-06-10
FI923494A0 (fi) 1992-08-03
KR927003521A (ko) 1992-12-18
AU652793B2 (en) 1994-09-08
GR3015567T3 (en) 1995-06-30
NO922968D0 (no) 1992-07-28
HU9202498D0 (en) 1992-10-28
EP0489579B1 (de) 1995-03-29
NO922967D0 (no) 1992-07-28
FI923494A (fi) 1992-08-03
GB2255339A (en) 1992-11-04
FI923495A0 (fi) 1992-08-03
WO1992009564A1 (en) 1992-06-11
GB2255339B (en) 1994-10-05
HU9202497D0 (en) 1992-10-28
DE69108363D1 (de) 1995-04-27
GB9211714D0 (en) 1992-08-26
WO1992009565A1 (en) 1992-06-11
DE69108529D1 (de) 1995-05-04
CA2073510A1 (en) 1992-06-04
DE69108529T2 (de) 1995-11-30
JPH05503720A (ja) 1993-06-17
GB2255340A (en) 1992-11-04
NO922968L (no) 1992-09-24
GB9211715D0 (en) 1992-08-26
DK0489579T3 (da) 1995-06-12
AU652596B2 (en) 1994-09-01
EP0489577A1 (de) 1992-06-10
AU9017391A (en) 1992-06-25
HUT61973A (en) 1993-03-29
GB2255340B (en) 1994-09-28
ES2069833T3 (es) 1995-05-16
FI923495A (fi) 1992-08-03
AU9023391A (en) 1992-06-25
HUT62263A (en) 1993-04-28
EP0489577B1 (de) 1995-03-22
NO922967L (no) 1992-09-24
JPH05503719A (ja) 1993-06-17

Similar Documents

Publication Publication Date Title
ATE120182T1 (de) Peptidylderivate.
AU645867B2 (en) 2-arylthiazole derivative and pharmaceutical composition containing the same
ATE71372T1 (de) Benzothiazol-derivat und es als aktiven bestandteil enthaltendes antirheumatisches mittel.
NO304111B1 (no) Heteroeddiksyrederivater, farmas°ytiske midler inneholdende dem samt deres anvendelse for fremstilling av farmas°ytiske preparater
DE69718306D1 (de) Piperidinylpyrimidine derivate
DK0487620T3 (da) Hidtil ukendte aminosyrederivater, fremgangsmåde til fremstilling heraf og terapeutisk anvendelse heraf
ES8702379A1 (es) Un procedimiento para la produccion de 1h-tetrazol-5-carboxamidas-n-sustituidas.
ATE497382T1 (de) Kosmetische oder pharmazeutische zubereitungen enthaltend 1,3,5-triazinderivate und zinkoxid
ATE84303T1 (de) Cysteinderivate.
DK363284A (da) Endo-8,8-dialkyl-8-azoniabicyclo/3.2.1/octan-6,7-exo-epoxy-3-alkylcarboxylatsalte, fremgangsmaade til fremstilling heraf og terapeutiske praeparater indeholdende disse
DE3861545D1 (de) Aminoverbindungen und diese enthaltende fungizide.
DK656889A (da) Azabicykliske derivater
DE2963724D1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
MD122C2 (ro) Procedeu de obţinere a derivaţilor oxadiazolilalchilpurinei sau a sărurilor ei acide aditive farmacologic acceptabile

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee